Company Filing History:
Years Active: 2013
Title: David Gordon: A Pioneer in Genetic Modification
Introduction: David Gordon is an accomplished inventor based in Doylestown, PA, known for his significant contributions to genetic research and modification. With a focus on therapeutic applications, he has developed innovative approaches to tackle metabolic disorders linked to the 11β-hydroxysteroid dehydrogenase type 1 (HSD1) enzyme.
Latest Patents: David Gordon holds a patent for his invention related to the 11β-hydroxysteroid dehydrogenase type 1. This patent describes gene-targeted non-human animals that are genetically modified to encode a mutant 11β-HSD1 polypeptide, which is modulated by human 11β-HSD1 compounds. Additionally, this invention encompasses cells that express this mutant 11β-HSD1 and methods for identifying agents that can regulate the activity of 11β-HSD1, providing valuable tools for treating related metabolic disorders.
Career Highlights: David currently works at Bristol-Myers Squibb Company, a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines. His work has contributed to advancements in understanding and treating complex metabolic conditions.
Collaborations: Throughout his career, David has collaborated with talented scientists such as Yuval Blat and Akbar Nayeem. Together, they have focused on the modulation of the 11β-HSD1 enzyme and its implications in metabolic health.
Conclusion: David Gordon's innovative work and patent in the field of genetic modification highlight his commitment to progressing medical science. His contributions are paving the way for new therapeutic strategies for metabolic disorders, and his collaborations emphasize the importance of teamwork in the pursuit of scientific discoveries.